



Tackling TKI-IO Toxicities Together

A Fireside Chat on aRCC Treatment



**ON-DEMAND CAPHO
SYMPOSIUM 2025
AVAILABLE SOON**

SPEAKERS



Glenn Myers

BScPharm, ACPR, RPh
(Chair-Speaker)

Clinical Pharmacist
Dr. Sheldon H Rubin Oncology Clinic
Moncton, NB



Maryam Soleimani

MD, FRCP(C)
(Speaker)

Clinical Assistant Professor,
University of British Columbia
Division of Medical Oncology
Medical Oncologist, BC Cancer,
Vancouver Centre
Vancouver, BC



Don Jacobsen

(Guest Speaker-Patient perspective)
Burnaby, BC

LEARNING OBJECTIVES

Having completed this learning activity, participants should be better able to:

Describe Overlapping Toxicities of TKI-IO Combinations:

Learn about the toxicities from combining TKIs and IO therapies in RCC treatment and strategies for managing them.

Enhance the Pharmacist's Role in Access and Adherence:

Explore how pharmacists ensure patient access to therapies and support adherence through education and management.

Implement Dose Individualization and Monitoring:

Develop skills in dose adjustments and monitoring to optimize outcomes, focusing on managing side effects and differences between TKIs and IO therapies.

This is a non-accredited learning program by Ipsen Biopharmaceuticals Canada Inc.